Cure8 news brief
If confirmed in later trials, a combo that increases endoscopic remission rates could offer a more effective treatment option for people with Crohn’s disease who don’t fully respond to single-agent biologics.
The news is also relevant because it may influence access, pricing, and prescribing patterns if the combo advances to approval.
Adults with Crohn’s disease, patients currently on biologics (especially risankizumab/Skyrizi), clinicians treating IBD, and researchers or investors following IBD drug development.
AbbVie reported Phase 2 data for ABBV-466, a two-antibody combination pairing Skyrizi (risankizumab) with a second antibody called trosunilimab. The article summarizes trial remission rates at weeks 12 and 24 that favored the combination over either monotherapy and notes slightly higher serious adverse event rates with the combo.
It is an investor-oriented piece interpreting the Phase 2 result as commercially significant but acknowledges that Phase 3 confirmatory trials are still needed.
The article is from a finance outlet that interprets Phase 2 trial data in commercial terms. ABBV-466’s Phase 2 results are promising but not confirmatory; Phase 3 studies and regulatory review are still required before approval and clinical use. Reported safety differences were modest but should be evaluated in larger trials.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Phase 2a data suggest a combo approach may improve endoscopic remission versus Skyrizi alone, which could matter for future Crohn's treatment options and for patients who have failed prior advanced therapies.
Treating fibrotic strictures would address an unmet need in Crohn’s disease — current approved drugs target inflammation, not established fibrosis. Positive Phase 2a signals could eventually lead to a new pharmacologic...
Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...
